Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · Real-Time Price · USD

560.00

-8.20 (-1.44%)

At close: Sep 12, 2025, 4:00 PM EDT

561.51

+1.51 (0.27%)

After-hours: Sep 12, 2025, 7:52 PM EDT

Regeneron Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Operating Revenue	13,655	13,687	12,581	11,808	15,791	7,940	Upgrade
Other Revenue	559.4	515	536.1	365.1	281.2	557	Upgrade
Revenue	14,214	14,202	13,117	12,173	16,072	8,497	Upgrade
Revenue Growth (YoY)	5.38%	8.27%	7.76%	-24.26%	89.14%	29.58%	Upgrade
Cost of Revenue	7,484	7,103	6,255	5,153	5,298	3,767	Upgrade
Gross Profit	6,731	7,100	6,862	7,020	10,774	4,730	Upgrade
Selling, General & Admin	2,774	2,954	2,631	2,116	1,825	1,346	Upgrade
Other Operating Expenses	-	-	-2.1	-89.9	-45.6	-280.4	Upgrade
Operating Expenses	2,774	2,954	2,629	2,026	1,779	1,066	Upgrade
Operating Income	3,957	4,145	4,233	4,994	8,995	3,665	Upgrade
Interest Expense	-36.6	-55.2	-73	-59.4	-57.3	-56.9	Upgrade
Interest & Investment Income	718.8	711.4	495.9	160.1	45.8	75.4	Upgrade
Currency Exchange Gain (Loss)	-0.5	-0.5	-12.9	50.2	0.4	-	Upgrade
Other Non Operating Income (Expenses)	41.3	15.8	-20	8.8	4	19.3	Upgrade
EBT Excluding Unusual Items	4,680	4,817	4,623	5,154	8,988	3,702	Upgrade
Gain (Loss) on Sale of Investments	310.9	117.7	-237.8	-39.8	386.1	196	Upgrade
Other Unusual Items	-23.5	-53.4	-	-	-	-	Upgrade
Pretax Income	4,875	4,780	4,199	4,859	9,326	3,810	Upgrade
Income Tax Expense	416.2	367.3	245.7	520.4	1,251	297.2	Upgrade
Net Income	4,459	4,413	3,954	4,338	8,075	3,513	Upgrade
Net Income to Common	4,459	4,413	3,954	4,338	8,075	3,513	Upgrade
Net Income Growth	3.17%	11.61%	-8.87%	-46.28%	129.86%	66.05%	Upgrade
Shares Outstanding (Basic)	107	108	107	107	106	108	Upgrade
Shares Outstanding (Diluted)	112	115	114	114	112	115	Upgrade
Shares Change (YoY)	-1.75%	1.23%	0.18%	1.16%	-2.52%	0.44%	Upgrade
EPS (Basic)	41.73	40.90	37.05	40.51	76.40	32.65	Upgrade
EPS (Diluted)	39.67	38.34	34.77	38.22	71.97	30.52	Upgrade
EPS Growth	5.03%	10.27%	-9.03%	-46.89%	135.81%	65.33%	Upgrade
Free Cash Flow	3,854	3,665	3,875	4,425	6,529	2,004	Upgrade
Free Cash Flow Per Share	34.29	31.84	34.08	38.98	58.19	17.41	Upgrade
Gross Margin	47.35%	49.99%	52.32%	57.67%	67.04%	55.67%	Upgrade
Operating Margin	27.84%	29.19%	32.27%	41.03%	55.97%	43.13%	Upgrade
Profit Margin	31.37%	31.07%	30.14%	35.64%	50.24%	41.35%	Upgrade
Free Cash Flow Margin	27.11%	25.80%	29.54%	36.35%	40.63%	23.58%	Upgrade
EBITDA	4,467	4,628	4,654	5,335	9,281	3,901	Upgrade
EBITDA Margin	31.42%	32.59%	35.48%	43.83%	57.75%	45.90%	Upgrade
D&A For EBITDA	510.1	482.9	421	341.4	286.2	235.9	Upgrade
EBIT	3,957	4,145	4,233	4,994	8,995	3,665	Upgrade
EBIT Margin	27.84%	29.19%	32.27%	41.03%	55.97%	43.13%	Upgrade
Effective Tax Rate	8.54%	7.68%	5.85%	10.71%	13.41%	7.80%	Upgrade
Revenue as Reported	14,214	14,202	13,117	12,173	16,072	8,497	Upgrade

Updated Aug 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q